Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped

Theo Rispens; Anke Vennegoor; Gert Jan Wolbink; Chris H. Polman; Joep Killestein

doi:https://doi.org/10.1177/1352458511431073

Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped

Theo Rispens, Anke Vennegoor, Gert Jan Wolbink, Chris H. Polman, Joep Killestein

Research output: Contribution to journal › Article › Academic › peer-review

37 Citations (Scopus)

Abstract

Natalizumab is frequently used as a treatment for multiple sclerosis (MS). The occurrence of progressive multifocal leukoencephalopathy (PML) in natalizumab-treated patients indicates that its prominent beneficial effects need to be balanced against the risks. Also, cessation of the drug seems to be associated with recurrence of disease activity. Both the moment of rebound disease activity and the outcome of PML are related to clearance of the drug. Specific features of this IgG4 antibody (i.e. half-antibody exchange) may result in underestimated drug levels. Here, we demonstrate natalizumab levels in 10 patients with relapsing MS, using a recently developed sensitive assay. Remarkably, natalizumab was detectable up to 200 days after cessation of therapy

Original language	English
Pages (from-to)	899-901
Journal	MULTIPLE SCLEROSIS JOURNAL
Volume	18
Issue number	6
DOIs	https://doi.org/10.1177/1352458511431073
Publication status	Published - 2012

Access to Document

https://doi.org/10.1177/1352458511431073

Cite this

@article{3b53ae2b4d154e7c878a9e31174ccf18,

title = "Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped",

abstract = "Natalizumab is frequently used as a treatment for multiple sclerosis (MS). The occurrence of progressive multifocal leukoencephalopathy (PML) in natalizumab-treated patients indicates that its prominent beneficial effects need to be balanced against the risks. Also, cessation of the drug seems to be associated with recurrence of disease activity. Both the moment of rebound disease activity and the outcome of PML are related to clearance of the drug. Specific features of this IgG4 antibody (i.e. half-antibody exchange) may result in underestimated drug levels. Here, we demonstrate natalizumab levels in 10 patients with relapsing MS, using a recently developed sensitive assay. Remarkably, natalizumab was detectable up to 200 days after cessation of therapy",

author = "Theo Rispens and Anke Vennegoor and Wolbink, {Gert Jan} and Polman, {Chris H.} and Joep Killestein",

year = "2012",

doi = "https://doi.org/10.1177/1352458511431073",

language = "English",

volume = "18",

pages = "899--901",

journal = "MULTIPLE SCLEROSIS JOURNAL",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "6",

}

TY - JOUR

T1 - Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped

AU - Rispens, Theo

AU - Vennegoor, Anke

AU - Wolbink, Gert Jan

AU - Polman, Chris H.

AU - Killestein, Joep

PY - 2012

Y1 - 2012

N2 - Natalizumab is frequently used as a treatment for multiple sclerosis (MS). The occurrence of progressive multifocal leukoencephalopathy (PML) in natalizumab-treated patients indicates that its prominent beneficial effects need to be balanced against the risks. Also, cessation of the drug seems to be associated with recurrence of disease activity. Both the moment of rebound disease activity and the outcome of PML are related to clearance of the drug. Specific features of this IgG4 antibody (i.e. half-antibody exchange) may result in underestimated drug levels. Here, we demonstrate natalizumab levels in 10 patients with relapsing MS, using a recently developed sensitive assay. Remarkably, natalizumab was detectable up to 200 days after cessation of therapy

AB - Natalizumab is frequently used as a treatment for multiple sclerosis (MS). The occurrence of progressive multifocal leukoencephalopathy (PML) in natalizumab-treated patients indicates that its prominent beneficial effects need to be balanced against the risks. Also, cessation of the drug seems to be associated with recurrence of disease activity. Both the moment of rebound disease activity and the outcome of PML are related to clearance of the drug. Specific features of this IgG4 antibody (i.e. half-antibody exchange) may result in underestimated drug levels. Here, we demonstrate natalizumab levels in 10 patients with relapsing MS, using a recently developed sensitive assay. Remarkably, natalizumab was detectable up to 200 days after cessation of therapy

U2 - https://doi.org/10.1177/1352458511431073

DO - https://doi.org/10.1177/1352458511431073

M3 - Article

C2 - 22183929

SN - 1352-4585

VL - 18

SP - 899

EP - 901

JO - MULTIPLE SCLEROSIS JOURNAL

JF - MULTIPLE SCLEROSIS JOURNAL

IS - 6

ER -